Walton Mike I, Wilson Stuart C, Hardcastle Ian R, Mirza Amin R, Workman Paul
Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton Surrey.
Mol Cancer Ther. 2005 Sep;4(9):1369-77. doi: 10.1158/1535-7163.MCT-04-0341.
The small-molecule compound pifithrin-alpha (PFT-alpha) has been reported to inhibit p53 function and protect against a variety of genotoxic agents. We show here that PFT-alpha is unstable in tissue culture medium and is rapidly converted to its condensation product PFT-beta. Both compounds showed limited solubility with PFT-alpha precipitating out of tissue culture medium at concentrations >30 micromol/L. PFT-alpha and -beta exhibited cytotoxic effects in vitro towards two human wild-type p53-expressing tumor cell lines, A2780 ovarian and HCT116 colon (IC(50) values for both cell lines were 21.3 +/- 8.1 micromol/L for PFT-alpha and 90.3 +/- 15.5 micromol/L for PFT-beta, mean +/- SD, n = 4). There was no evidence of protection by clonogenic assay with either compound in combination with ionizing radiation. Indeed, there was some evidence that PFT-alpha enhanced cytotoxicity, particularly at higher concentrations of PFT-alpha. Neither compound had any effect on p53, p21, or MDM-2 protein expression following ionizing radiation exposure and there was no evidence of any abrogation of p53-dependent, ionizing radiation-induced cell cycle arrest. Similarly, there was no evidence of cellular protection, or of effects on p53-dependent gene transcription, or on translation of MDM-2 or p21 following UV treatment of these human tumor cell lines. In addition, there was no effect on p53 or p21 gene transactivation or p38 phosphorylation after UV irradiation of NIH-3T3 mouse fibroblasts. In conclusion, neither PFT-alpha nor -beta can be regarded as a ubiquitous inhibitor of p53 function, and caution should be exercised in the use of these agents as specific p53 inhibitors.
据报道,小分子化合物pifithrin-α(PFT-α)可抑制p53功能,并抵御多种基因毒性剂。我们在此表明,PFT-α在组织培养基中不稳定,会迅速转化为其缩合产物PFT-β。两种化合物的溶解度都有限,当浓度>30微摩尔/升时,PFT-α会从组织培养基中沉淀出来。PFT-α和-β在体外对两种表达人野生型p53的肿瘤细胞系,即A2780卵巢癌细胞系和HCT116结肠癌细胞系,均表现出细胞毒性作用(两种细胞系的半数抑制浓度(IC50)值:PFT-α为21.3±8.1微摩尔/升,PFT-β为90.3±15.5微摩尔/升,均值±标准差,n = 4)。克隆形成试验表明,这两种化合物与电离辐射联合使用时均无保护作用。实际上,有证据表明PFT-α会增强细胞毒性,尤其是在较高浓度的PFT-α时。电离辐射暴露后,这两种化合物对p53、p21或MDM-2蛋白表达均无影响,也没有证据表明p53依赖性的、电离辐射诱导的细胞周期停滞被消除。同样,对这些人肿瘤细胞系进行紫外线处理后,也没有细胞保护的证据,也没有对p53依赖性基因转录、MDM-2或p21翻译产生影响的证据。此外,对NIH-3T3小鼠成纤维细胞进行紫外线照射后,对p53或p21基因反式激活或p38磷酸化均无影响。总之,PFT-α和-β都不能被视为p53功能的普遍抑制剂,在将这些试剂用作特异性p53抑制剂时应谨慎。